This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-11. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
=== Pharmacogenomics === Genetic factors explain 49% of the pain response variance in the cold pressor test. Further the response variance to analgesia using alfentanil in the cold pressor test can be attributed to genetic effects at 60%. Morphine and its metabolites directly interact with several proteins, including: UGT2B7, OCT1 (SLC22A1), μ-opioid receptor (OPRM1), and P-glycoprotein (ABCB1 or MDR1). Furthermore catechol-O-methyltransferase indirectly affects efficacy of morphine.
== Fetal tolerance to noninherited maternal antigens == Fetal T cells accumulate during in utero development. Even though the fetus is exposed to noninherited maternal antigens (NIMAs), fetal CD4+ T cells are capable of alloantigen-induced proliferation, preferentially differentiating to Treg cells and preventing a fetal immune response to maternal antigens. This expanded immune tolerance persists in both mother and offspring after birth and allows microchimeric cells to be retained in tissues.
The B1 receptor (also called bradykinin receptor B1) is expressed only as a result of tissue injury, and is presumed to play a role in chronic pain. This receptor has been also described to play a role in inflammation. It was shown that the kinin B1 receptor recruits neutrophils via the chemokine CXCL5 production. Moreover, endothelial cells have been described as a potential source for this B1 receptor-CXCL5 pathway. The B2 receptor is constitutively expressed and participates in bradykinin's vasodilatory role. The kinin B1 and B2 receptors belong to G protein coupled receptor (GPCR) family.
Sources: en.wikipedia.org
9 February – Donald Cameron, a Conservative list MSP for the Highlands and Islands, announces he is standing down from the Scottish Parliament to take up a seat in the House of Lords and a junior ministerial post in the Scottish Office. 10 February – Police Scotland are investigating 22 deaths that occurred at the Fullarton Care Home in Irvine, North Ayrshire during the COVID-19 pandemic. The home was one of the worst affected during the early days of the pandemic. 11 February – Canadian woman Claire Leveque, aged 24, dies following a disturbance in Sandness, Shetland. Aren Pearson is subsequently charged with her murder. 12 February – Actor and writer Simon Fanshawe is named the new Rector of the University of Edinburgh, succeeding Debora Kayembe. A man is arrested and charged over several acts of vandalism in Glasgow, including graffiti relating to the Gaza conflict daubed on the city's cenotaph. 13 February – Former NHS worker Tracy Menhinick, who gave a young boy "industrial amounts" of the laxative lactulose, is found guilty of poisoning the child following a 19-day trial at the High Court in Aberdeen. 14 February – Jordan Mitchell, who spoke about his desire to commit mass murder in Falkirk during a hospital visit, and who said he had killed animals, is given an Order for Lifelong Restriction by the Court of Criminal Appeal. 15 February – Glasgow City Council and North Lanarkshire Council vote to freeze council tax for the 2024–25 financial year.
The outermost wall of the organ is known as the parietal layer The skin of the organ is known as the visceral layer. The organs have specialized names for their visceral fasciae. In the brain, they are known as meninges; in the heart they are known as pericardia; in the lungs, they are known as pleurae; and in the abdomen, they are known as peritonea. Visceral fascia is less extensible than superficial fascia. Due to its suspensory role for the organs, it needs to maintain its tone rather consistently. If it is too lax, it contributes to organ prolapse, yet if it is hypertonic, it restricts proper organ motility.
The cap of P. semilanceata is 5–25 mm (0.20–0.98 in) in diameter and 6–22 mm (0.24–0.87 in) tall. It varies in shape from sharply conical to bell-shaped, often with a prominent papilla (a nipple-shaped structure), and does not change shape considerably as it ages. The cap margin is initially rolled inward but unrolls to become straight or even curled upwards in maturity. The cap is hygrophanous, meaning it assumes different colors depending on its state of hydration. When it is moist, the cap is ochraceous to pale brown to dark chestnut brown, but darker in the center, often with a greenish-blue tinge. When moist, radial grooves (striations) can be seen on the cap that correspond to the positions of the gills underneath. When the cap is dry, it becomes much paler, a light yellow-brown color. Moist mushrooms have sticky surfaces that result from a thin gelatinous film called a pellicle. This film becomes apparent if a piece of the cap is broken by bending it back and peeling away the piece. When the cap dries from exposure to the sun, the film turns whitish and is no longer peelable. On the underside of the mushroom's cap, there are between 15 and 27 individual narrow gills that are moderately crowded together, and they have a narrowly adnexed to almost free attachment to the stipe. Their color is initially pale brown, but becomes dark gray to purple-brown with a lighter edge as the spores mature. The slender yellowish-brown stipe is 4.5–14 cm (1.8–5.5 in) long by 1–3.5 mm (0.04–0.14 in) thick, and usually slightly thicker towards the base.
In 2020, Chen Xiaojiang was appointed as head of the National Ethnic Affairs Commission, the first Han Chinese head of the body since 1954. On 24 June 2022, Pan Yue, another Han Chinese, became the head of the commission, with him reportedly holding assimilationist policies toward ethnic minorities. Xi outlined his official views relations between the majority Han Chinese and ethnic minorities by saying "[n]either Han chauvinism nor local ethnic chauvinism is conducive to the development of a community for the Chinese nation." Xi's policies toward ethnic minorities were codified in the Law on Promoting Ethnic Unity and Progress in 2026.
Sources: en.wikipedia.org
=== Mechanism of action === Flupentixol inhibits dopamine-mediated effects by acting as an antagonist at the D(2) and D(1a) dopamine receptors. It also acts as a 5-HT2 receptor antagonist. Melitracen is a TCA with anxiolytic properties. At low doses, it has activating properties. It is also a bipolar thymoleptic. The exact mechanism of Action is not fully understood.
An exhaustive review article published in March 2009 described the latest information on arteritic and non-arteritic ischemic optic neuropathy, both anterior (A-AION and NA-AION) and posterior (A-PION, NA-PION, and surgical).
Naja annulata (formerly Boulengerina annulata), commonly known as the banded water cobra or the ringed water cobra, is a species of water cobra native to western and central Africa. The species is one of the two species of water cobra in the world, the other one being the Congo water cobra (Naja christyi).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.